Form 4: Aura Bio SVP Exercises Options, Sells Shares

Aura Biosciences' Senior VP of Finance, Amy Elazzouzi, exercised stock options and sold a portion of the acquired shares to cover costs.

Summary

• Amy Elazzouzi, Senior Vice President of Finance at Aura Biosciences, Inc., exercised long-held stock options on August 18, 2025.
• The exercise involved purchasing a total of 12,899 shares of common stock at various exercise prices ranging from $2.74 to $5.48 per share.
• Of the acquired shares, 7,722 were subsequently sold at a weighted average price of $6.70 per share to cover the exercise costs and taxes.
• Following these transactions, Amy Elazzouzi directly owns 86,558 shares of Aura Biosciences common stock.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The transaction is routine for executive compensation, indicating a realization of value by the executive. The sale to cover costs is standard and not indicative of a negative outlook, but also not a strong positive signal of increased insider confidence.

Positives

• The exercise of options indicates a realization of value by a senior executive from their equity compensation.
• The sale price of $6.70 per share is higher than all the exercise prices, indicating a profitable transaction for the executive.

Negatives

• A portion of the shares acquired through option exercise was immediately sold, which, while stated to cover exercise costs, represents a reduction in the executive's direct equity exposure to the company.

Future Outlook

This filing is a transaction report and does not contain forward-looking statements or guidance regarding the company's future performance.

Management Comments

• The filing notes that the 7,722 shares were sold to cover the exercise price of the options.

Industry Context

This is an insider transaction filing, common across all industries, reflecting an executive's management of their equity compensation. It does not directly relate to broader industry trends but rather to individual executive compensation strategies within Aura Biosciences.

Comparison to Industry Standards

• Insider transactions like option exercises and sales to cover costs are standard practices for executives across publicly traded companies. The specific prices and volumes are unique to Aura Biosciences and its executive compensation structure, but the mechanism is consistent with industry norms for managing vested equity awards.

Stakeholder Impact

• Shareholders: Provides transparency into executive equity compensation and holdings. The sale of shares to cover costs is a common practice and does not necessarily indicate a lack of confidence, but rather a management of personal finances related to equity awards.

Next Steps

• The filing does not specify any future actions or milestones for the company, as it is a report of past executive transactions.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where a senior executive exercised stock options and sold a portion of the acquired shares to cover the exercise price. This is a common practice for managing equity compensation and does not inherently signal a change in the company's fundamental outlook or performance. While the executive realized a profit on the options, the transaction itself is not a strong indicator for a 'buy' or 'sell' recommendation. Investors should look to broader company financial reports and strategic updates for investment decisions.

Keywords

Aura Biosciences, AURA, SEC Form 4, Insider Trading, Stock Options, Executive Compensation, Amy Elazzouzi, Share Sale, Option Exercise